IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The business had revenue of $6.56 million for the quarter, ...

IDEAYA Biosciences posted $6.6M collaboration revenue and a $98.5M net loss in Q1 2026, while ending the quarter with $972.9M in cash and securities to fund its oncology pipeline.

Is IDYA a good stock to buy? We came across a bullish thesis on IDEAYA Biosciences, Inc. on Valueinvestorsclub.com by pestopenguin. In this article, we will summarize the bulls’ thesis on IDYA. IDEAYA Biosciences, Inc.’s share was trading at $29.48 as of April 27th.

IDEAYA Biosciences ( ($IDYA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement. IDEAYA Biosciences shares are under ...

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral...